InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (2 ops.)
Insider track record
CEODisclosed buys
1
Disclosed sells
2
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Klausner Richard, Président Exécutif. Director active across 2 companies, notably Lyell Immunopharma, Inc.. In total, 5 reports have been published. Split: 1 buy · 2 sells. Total volume traded: €281k. History available since 23 September 2022. The latest transaction was filed on 14 March 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Klausner Richard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
158,000 shares@ US$0.600931.1% of flowCommon StockSEC:0001415889-25-008540:0
Canonical exit: 12 Jun 2025 (T+90)
58,020 shares@ US$2.2843.2% of flowCommon StockSEC:0001209191-23-046267:0
11,100 shares@ US$6.400125.7% of flowCommon StockSEC:0001209191-22-051379:0
3,765,842 sharesCommon StockSEC:0001209191-21-042798:0
253 sharesCommon StockSEC:0001127602-16-038840:0
5 of 5 declarations
About Klausner Richard
Richard Klausner is the Executive Chairman of Lyell Immunopharma, Inc. He plays a key role in the strategic direction of the company, bringing his expertise in biotechnology and drug development. His role as a board member includes overseeing performance and evaluating initiatives aimed at enhancing innovation and research. He ensures that Lyell Immunopharma meets its performance and innovation objectives.
